Precigen (NASDAQ:PGEN) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.
Valuation & Earnings
This table compares Precigen and AIkido Pharma’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Precigen||$90.72 million||9.26||-$322.32 million||($0.88)||-5.55|
|AIkido Pharma||$10,000.00||2,863.44||-$4.18 million||N/A||N/A|
Risk & Volatility
Precigen has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, AIkido Pharma has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
This table compares Precigen and AIkido Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
75.7% of Precigen shares are held by institutional investors. Comparatively, 0.9% of AIkido Pharma shares are held by institutional investors. 50.7% of Precigen shares are held by insiders. Comparatively, 4.2% of AIkido Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Precigen and AIkido Pharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Precigen presently has a consensus price target of $9.25, suggesting a potential upside of 89.55%. Given Precigen’s higher probable upside, research analysts plainly believe Precigen is more favorable than AIkido Pharma.
Precigen beats AIkido Pharma on 8 of the 11 factors compared between the two stocks.
Precigen Company Profile
Precigen, Inc. engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
AIkido Pharma Company Profile
AIkido Pharma Inc., a biotechnology development company, focuses on developing small-molecule anti-cancer therapeutics. The company engages in the development of therapeutic drugs for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Its portfolio includes KPC-34 for the treatment of AML and ALL; and DHA-dFdC drug for the treatment of pancreatic cancer. AIkido Pharma Inc. has an artificial intelligence and machine learning research agreement with Cogia Biotech LTD. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2020. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.